A survey of more than 100 oncologists suggests that doctors are increasingly using Roche/Plexxikon's Zelboraf to treat metastatic melanoma patients whose tumors harbor BRAF gene mutations.

The survey, by BioTrends Research Group, also revealed that with rising adoption of the drug, doctors are becoming more comfortable with the use of molecular screening to inform treatment strategies for melanoma patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.